Current Report Filing (8-k)
February 26 2021 - 6:55AM
Edgar (US Regulatory)
0001280776
false
0001280776
2021-02-26
2021-02-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): February 26, 2021
IMMUNIC, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
001-36201
|
56-2358443
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
1200 Avenue of the Americas, Suite 200
New York, NY 10036
USA
(Address of principal executive offices)
Registrant’s telephone number,
including area code: (332) 255-9818
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of exchange on which registered
|
Common Stock, par value $0.0001
|
IMUX
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. Yes ☐
No ☐
Item 2.02. Results of Operations and Financial
Condition
On February 26, 2021, Immunic, Inc. (the “Company”)
issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results
for the quarter and year ended December 31, 2020 and providing a corporate update (the “Press Release”).
The information contained in Item 2.02 of
this Current Report on Form 8-K, including the Press Release, shall not be deemed “filed” for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference
into any of the Company’s filings with the Securities and Exchange Commission, except as shall be expressly set forth by
specific reference in any such filing.
Item 8.01 - Other Events.
On February 26, 2021, the Company posted an
updated corporate presentation on its website. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated
herein by reference.
Item 9.01. Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Dated: February 26, 2021
|
Immunic, Inc.
|
|
|
|
|
By:
|
/s/ Daniel Vitt
|
|
|
Daniel Vitt
|
|
|
Chief Executive Officer
|
Immunic (NASDAQ:IMUX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immunic (NASDAQ:IMUX)
Historical Stock Chart
From Apr 2023 to Apr 2024